Results 51 to 60 of about 18,490 (188)

Bispecific antibodies in follicular lymphoma

Haematologica
Bispecific antibodies, specifically anti-CD20 T-cell engaging constructs, are poised to alter the treatment paradigm of multiple B-cell malignancies, including follicular lymphoma. Two CD20xCD3 bispecific antibodies, mosunetuzumab and epcoritamab, are now approved in the United States for third-line or later treatment of follicular lymphoma.
Imran A. Nizamuddin, Nancy L. Bartlett
openaire   +3 more sources

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, EarlyView.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Beta cells to brain cells: The pivotal role of insulin and glucose metabolism in Alzheimer's disease

Neuroprotection, EarlyView.
Common metabolic, histochemical, and molecular pathologies: Type 2 diabetes and dementia. Abstract The risk factors and neuropathologies of cognitive decline and the onset and progression of dementia‐related disorders were, until recently, obtuse. A critical predisposing factor to Alzheimer's disease (AD) that has emerged is glucose dysmetabolism.
Stanley S. Schwartz, Elizabeth M. Rhea, William A. Banks, Mary E. Herman   +3 more
wiley   +1 more source

Hemophilia A: An Ideal Disease for Prenatal Therapy

Prenatal Diagnosis, EarlyView.
ABSTRACT Hemophilia A (HA) is the most common inherited coagulation defect. Current state‐of‐the‐art treatment consists of frequent administration of prophylactic infusions of coagulation factor VIII (FVIII) protein or bispecific antibodies that replace the cofactor function of FVIIIa to maintain hemostasis. However, these treatments are far from ideal,
Christopher D. Porada, Anthony Atala, Graça Almeida‐Porada   +2 more
wiley   +1 more source

A REVIEW ON BISPECIFIC ANTIBODIES

, 2019
Antibodies are widely recognized for their therapeutic potential and subsequently have prompted a lot of interest into their development and application. The structure of monoclonal IgG antibody is represented, with the heavy chains in rose and the light chains in green.
openaire   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

A Model‐Based Approach to Evaluate Anti‐Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T‐Cell Bispecific Cibisatamab

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT The administration of biologics can lead to immunogenic responses that trigger anti‐drug antibody (ADA) formation. ADAs can decrease drug exposure. A population pharmacokinetic (popPK) model was developed to describe clinical PK data with and without ADA‐driven exposure loss with CEA‐directed T‐cell bispecific antibody cibisatamab.
Javier Sanchez, Philippe B. Pierrillas, Nicolas Frey, Gregor P. Lotz, Siv Jönsson, Lena E. Friberg, Nicolas Frances   +6 more
wiley   +1 more source

Development of a Heuristic Machine Analogy Method for Model Simplification With an Application to a Large‐Scale Model of Gi/Gs Signaling

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Model simplification is a process to simplify large‐scale mathematical models to enable easy applications such as simulation and parameter estimation. A novel heuristic machine analogy method of model simplification was developed and applied to a motivating example of a model for cAMP signaling switch induced by Gi/Gs pathway competition for ...
Liang Yang, David Finlay, Michelle Glass, Stephen Duffull   +3 more
wiley   +1 more source

Potential roles of antibodies with different classes in IgG4‐related diseases

Rheumatology &Autoimmunity, EarlyView.
This review discussed the common characteristics of different classes of antibodies and their potential corresponding unique mechanisms involved in immunoglobulin G4‐related disease. Abstract Immunoglobulin G4‐related disease (IgG4‐RD), first identified two decades ago, is an immune‐mediated pro‐inflammatory and profibrotic disease entity affecting ...
Ling Li, Shaozhe Cai, Shengyan Lin, Lin Bai, Zhihua Yu, Wei Sun, Lingli Dong   +6 more
wiley   +1 more source

The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC

VIEW, EarlyView.
Background The interaction between TIGIT and CD155 compromises immune cell efficacy in tumor targeting, potentially driving hepatocellular carcinoma (HCC) progression through diverse molecular pathways. What Was Done This study investigates the interplay between CD155 and TIGIT in regulating CD8+ T cell function and elucidates its implications in HCC ...
Wenting Li, Yukun Li, Yao Li, Mingqi Yang, Haichuan Peng, Hongwei Sun, Ping Jiang, Yizhun Zhu, Qiang Chen, Xiaobing Duan, Wei Zhao   +10 more
wiley   +1 more source